CRAMS – a new business model for Indian pharmaceuticals.

CRAMS – a new business model for Indian pharmaceuticals.

The Contract Research and Manufacturing Services (CRAMS) has been an emerging business model for indian pharmaceutical inductry . At present this business is seems to cover more than $1 billion annually and increasing with 25 % pa. Currently CRAMS is accounted for 6-8 % of indian pharma business. Over the past few years India's popularity as a hub for pharmaceutical research and development (R&D) has grown. Most of the well established indian discovery based pharmaceuticals have spinned off their discovery activitie to CRAMS. There are many new organizations focusing contract business in the ares of bioanalysis, medicinal chemistry, insilico-sreening, pharmacology and toxicology. Global pharmaceutical companies are also increasingly outsourcing early-stage drug discovery to India, as it provides a reduced research cost with good infrastruture and has a large pool of english speaking professionals.
Leading Indian CROs include, Matrix, Chembiotech, Jublient, Suven life sciences and Syngene. While other pharmaceuticals conducing their own drug discovery as well as offering contract services are Dr. reddy’s lab, Advinus Theraputics, Torrent Pharma and Nicholas Piramal.
Contract manufacturing is another segment of CRAMS, where indian organizations are providing world class standards in munufacturing with less cost . A large number of manufacturing facilities approved by US FDA, Australian-TGA, UKMCA, and EMEA are advantageous for the growth in this section . Leading players in contract manufacturing are Divi's Laboratories , Dishman Pharmaceuticals, Shasun Chemicals & Drugs etc.
Another sets of players are in clinical research and database management of Phase I-IV clinical trials. Manipal Acunova, Veeda Clinical Research, SIRO Clinpharm are few of them .
Overall india has this booming area to enjoy it advantages over other countries, however india could face some competition from China Korea and Eastern Europe.


SAM